|
Abstract
Interference of Homologous Sequences on the SNP Study of CYP2A13 Gene
Feng HUA, Haisu WAN, Chaorong MEI, Dejie ZHENG, Linlin SUN, Jun CHEN, Hongyu LIU, Qinghua ZHOU
Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenviroment, Tianjin Lung Cancer Institute,
Tianjin Medical University General Hospital, Tianjin 300052, China
Corresponding author: Qinghua ZHOU, E-mail: zhouqh1016@yahoo.com.cn
【Abstract】Background and objective It has been proven that cytochrome P450 enzyme 2A13 (CYP2A13) played an important role in the association between single nucleotide polymorphisms (SNP) and human diseases. Cytochrome P450 enzymes are a group of isoenzymes, whose sequence homology may interfere with the study for SNP. The aim of this study is to explore the interference on the SNP study of CYP2A13 caused by homologous sequences. Methods Taqman probe was applied to detect distribution of rs8192789 sites in 573 subjects, and BLAST method was used to analyze the amplified sequences. Partial sequences of CYP2A13 were emplified by PCR from 60 cases. The emplified sequences were TA cloned and sequenced. Results For rs8192789 loci in 573 cases, only 3 cases were TT, while the rest were CT heterozygotes, which was caused by homologous sequences. There are a large number of overlapping peaks in identical sequences of 60 cases, and the SNP of 101 amino acid site reported in the SNP database is not found. The cloned sequences are 247 bp, 235 bp fragments. Conclusion The homologous sequences may interfere the study for SNP of CYP2A13, and some SNP may not exist.
【Key words】Cytochrome P450 2A13; Single nucleotide polymorphisms; Homologous sequences
This study was partly supported by grants from the National Eleventh-Five-Year Key Task Project of China (to Qinghua ZHOU)(No.2006BAI02A01), National 863 Project (to Qinghua ZHOU)(No.2006AA02401) and Tianjin Scientific Supporting Project, China-Sweden Cooperative Foundation (to Qinghua ZHOU)(No.09ZCZDSF04100).
|
|
参考文献
- Li J, Pan YC, Li YX, et al. Analysis and application of SNP and haplotype in the human genome. Yichuan Xue Bao, 2005, 32(8): 879-889.[LinkOut]
- Giacomini KM, Brett CM, Altman RB, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther, 2007, 81(3): 328-345.[LinkOut]
- Sobrino B, Brion M, Carracedo A. SNPs in forensic genetics:a review on SNP typing methodologies. Forensic Sci Int, 2005,154(2-3): 181-194.[LinkOut]
- Suh Y, Vijg J. SNP discovery in associating genetic variation with human disease phenotypes. Mutat Res, 2005, 573(1-2): 41-53.[LinkOut]
- Zhang X, D'Agostino J, Wu H, et al. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. J Pharmacol Exp Ther, 2007, 323(2): 570-578.[LinkOut]
- Su T, Bao Z, Zhang QY, et al. Human cytochrome P450 CYP2A13:predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen,4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res, 2000, 60(18): 5074-5079.[LinkOut]
- D'Agostino J, Zhang X, Wu H, et al. Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers. Drug Metab Dispos, 2008, 36(11): 2316-2323.[LinkOut]
- Timofeeva MN, Kropp S, Sauter W, et al. CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences. Carcinogenesis, 2009, 30(7): 1161-1169.[LinkOut]
- Wang H, Tan W, Hao B, et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res, 2003, 63(22): 8057-8061.[LinkOut]
- Cauffiez C, Lo-Guidice JM, Quaranta S, et al. Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. Biochem Biophys Res Commun, 2004, 317(2): 662-669.[LinkOut]
- He XY, Tang L, Wang SL, et al. Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int J Cancer, 2006, 118(11): 2665-2671.[LinkOut]
- von Weymarn LB, Chun JA, Hollenberg PF. Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers. Carcinogenesis, 2006, 27(4): 782-790.[LinkOut]
- Zhu LR,Thomas PE, Lu G, et al. CYP2A13 in human respiratory tissues and lung cancers:an immunohistochemical study with a new peptide-specific antibody. Drug Metab Dispos, 2006, 34(10): 1672-1676.[LinkOut]
- Ling G, Wei Y, Ding X. Transcriptional regulation of human CYP2A13 expression in the respiratory tract by CCAAT/enhancer binding protein and epigenetic modulation. Mol Pharmacol, 2007, 71(3): 807-816.[LinkOut]
- Smith BD, Sanders JL, Porubsky PR, et al. Structure of the human lung cytochrome P450 2A13. J Biol Chem, 2007, 282(23): 17306-17313.[LinkOut]
- Phillips C. Online resources for SNP analysis: a review and route map. Mol Biotechnol, 2007, 35(1): 65-97.[LinkOut]
|